Chebet sets world record, breaks 14-minute barrier
Kenya’s Beatrice Chebet broke the women’s 5000-metre world record on Saturday, becoming the first woman in history to run the distance in under 14...
German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said.
CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at €1.04 billion ($1.2 billion), while BioNTech shares were down 2%.
The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke.
"With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," the company said.
CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK.
It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic.
GERMAN BIOTECH CHAMPION
The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress.
CureVac shares were worth as much as €120 in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at €4.65.
BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda.
Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said.
If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.
BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac.
The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer.
A magnitude 5.5 earthquake struck off Japan’s Tokara Islands on Wednesday, with no tsunami warning issued but residents advised to remain vigilant.
The United States has rescinded licensing restrictions on ethane exports to China, allowing shipments to resume after a temporary halt and signalling progress in efforts to ease recent trade tensions.
Italy plans to grant approximately 500,000 work visas to non-EU nationals between 2026 and 2028, as announced in a cabinet statement. The initiative aims to address labor shortages by expanding legal immigration pathways
Following a deadly glacier collapse in Blatten, near the Swiss Alpine village of Kandersteg, the town is on high alert as melting permafrost and shifting rock threaten another potential disaster after it was buried a month ago.
A malfunction in the radar transmission system at the Area Control Center in Milan suspended more than 300 flights at the weekend, across northwest Italy since Saturday evening according to Italy's air traffic controller Enav (National Agency for Flight Assistance).
France will impose its toughest outdoor smoking restrictions starting Monday, banning smoking at beaches, parks, playgrounds, and bus stops.
Scientists in Australia and the U.S. have developed an AI tool that could transform cancer care by revealing the hidden diversity of tumour cells and guiding more targeted therapies.
Singapore has launched its largest-ever study on paediatric food allergies, aiming to better understand and address the growing burden of allergic reactions among children.
Bill Gates says his foundation will not compensate for funding shortfalls caused by U.S. and UK aid cuts to global vaccination efforts, warning of rising child mortality as a result.
The world is facing a health financing emergency as global health investment risks falling to its lowest level in a decade, the World Health Organization (WHO) warned.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment